Hutchmed China Ltd ADR (HCM)

$HCM https://wallstreetwaves.com/hcm-surges-past-key-moving-average-with-bullish-momentum/

$HCM Hutchmed, Innovent jointly announce NDA acceptance in China HUTCHMED and Innovent Biologics "jointly announce that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for review by the China National Medical Products Administration. The NDA is supported by data from FRUSICA-2, a randomized, open-label, active-controlled registration study evaluating the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy for the second-line treatment of advanced renal cell carcinoma. The study has met its primary endpoint of progression free survival, as assessed by blinded independent central review according to RECIST 1.1 criteria. The combination also demonstrated improvements in secondary endpoints including objective response rate and duration of response. The safety profile was tolerable and no new safety signals were observed. Data from FRUSICA-2 will be submitted for presentation at an upcoming scientific conference."

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics $HCM https://stocktwits.com/news/equity/markets/hutchmed-stock-hits-over-one-month-high-after-china-accepts-kidney-cancer-nda-filed-with-partner-innovent-biologics/chkDEXyRbDf

HUTCHMED Reports Positive Results from SACHI Phase III Study of Savolitinib and Osimertinib in EGFR Mutation-Positive NSCLC. Read more about $HCM: https://www.quiverquant.com/news/HUTCHMED+Reports+Positive+Results+from+SACHI+Phase+III+Study+of+Savolitinib+and+Osimertinib+in+EGFR+Mutation-Positive+NSCLC

RECAP 5/13 -Neg Comments: $ITOS - JPM $HCM - HSBC $QIPT - Canaccord Live Breaking trading news www.openoutcrier.com

WATCHLIST APR 23 2025. $GNPX Genprex Announces Research Collaborators' Abstract Published In Cancer Research Supplement Proceedings On The Use Of Reqorsa Gene Therapy For The Treatment Of Lung Cancer $MASS 908 Devices shares are trading higher after the company announced it received a $2 million order from the Texas Department of Public Safety for Drug Detection and Mitigation $HCM HUTCHMED shares are trading higher after the company announced it completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification. $DKNG Barclays Maintains Overweight on DraftKings, Lowers Price Target to $50 $NNE NANO Nuclear And University of Illinois Urbana-Champaign Receives Nuclear Regulatory Commission Fuel Qualification Methodology Approval For KRONOS MMR Energy System

$HCM HUTCHMED shares are trading higher after the company announced it completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification.

$HCM whats up ?

$HCM Hutchmed says NDA for Tazverik granted conditional approval in China Hutchmed announces that the New Drug Application for Tazverik has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies. This approval follows the priority review status by the National Medical Products Administration and marks the first nationwide regulatory approval for Tazverik in China.

$HCM Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M HUTCHMED provides full year 2025 guidance for Oncology/Immunology consolidated revenue of $350 million to $450 million. HUTCHMED's work in 2025 and beyond will be supported by its strong balance sheet. The Company will continue to be financially self-reliant while supporting investments to bring innovative medicines to patients globally.

$HCM Hutchmed reports FY24 EPS 22c vs. 59c last year Reports revenue $630.2M vs. $838M last year. an Eldar, Non-executive Chairman of HUTCHMED, said, "The successful commercialization of FRUZAQLA outside of China by our partner Takeda and the resulting milestones achieved during the year were pivotal in helping HUTCHMED reach its profitability goals. I am proud that, at times of uncertainty in the global environment and in the capital markets, we have successfully established an independent ability to support our valuable discovery engine and development pipeline while mitigating operational risks. We expect to continue our global growth with further sales in the US and in other regions of the world, while continuing to develop our pipeline in new and promising directions. The long-term interests of our shareholders and benefits to patients around the world will always remain our top priorities. At the end of 2024, we decided to dispose of our 45% equity interest in SHPL for $608 million, subject to closing conditions. I would like to take this opportunity to express my appreciation to the management team at SHPL for their contribution to its impressive growth over the last 20 years, which has delivered consistent benefits to consumers and shareholders alike. The commercial success and monetary contribution were important in supporting HUTCHMED's novel drug R&D19, helping us to weather challenges in our industry as we developed innovative medicines for patients in need. As our innovative drugs business has become more self-reliant, we believe it is time for HUTCHMED to move on to our next phase of evolution, particularly as we focus on global clinical development of our ATTCs. The proceeds from the SHPL disposal, on top of the ongoing profits of our globally commercialized portfolio, enables us to expedite the roll-out of this differentiated platform, which will be key to our long-term value creation."

$HCM HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China "FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma ("RCC") in China has met its primary endpoint of progression free survival ("PFS") per RECIST 1.1 as assessed by blinded independent central review (BICR)."

$HCM Hutchmed/Innovent update on Phase 2/3 study of Fruquintinib+Sintilimab Hutchmed and Innovent Biologics "jointly announce that the FRUSICA-2 Phase2/3 clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China has met its primary endpoint of progression free survival per RECIST 1.1 as assessed by blinded independent central review. The combination of fruquintinib and sintilimab received conditional approval from the China National Medical Products Administration for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study."

$HCM's upcoming earnings report draws attention amid stabilizing margins and recent volume growth. Options activity reflects balanced risk sentiment, with implied volatility near 6M avg. Markets await execution updates on strategic initiatives while monitoring Rx drug policy impacts.

EcoR1 Capital, a 10% owner of $ZYME, has been accumulating shares aggressively. In recent months, EcoR1 purchased approximately 2.6M shares worth $33.8M, most recently acquiring 1.1M shares at $12.13 on March 11, 2025. This buying coincides with Zymeworks' strategic roadmap for 2025-2026: IND applications for ZW220 (bispecific antibody for solid tumors) and ZW251 (ADC targeting B7-H4) expected in 2025. Phase 3 HERIZON-GEA-01 results for zanidatamab (Ziihera®) in gastric cancer are due in Q2-2025. The company reported $324M in cash as of Q4-2024, providing runway into H2-2027. JPMorgan recently upgraded ZYME to "overweight" with an $18 target. While this insider accumulation alongside upcoming catalysts suggests positive internal sentiment, investors should weigh this against the stock's recent volatility and mixed analyst forecasts. Worth watching for insider activity: $VRTX, $BHVN, $HCM. Insider details at https://prismo.pro/stock/zyme?utm_source=stockwits&utm_medium=social&utm_campaign=insider-news&utm_content=ZYME_2025-03-14 🚀 #InsiderTrading

WATCHLIST MAR 06 2025 $QGEN QIAGEN Announced That The U.S. Food And Drug Administration (FDA) Has Cleared The QIAstat-Dx Gastrointestinal Panel 2 Mini B For Clinical Use, Further Strengthening Its Syndromic Testing Portfolio In The United States $FCEL FuelCell Energy and MMHE Partner to Expand Large-Scale Hydrogen Production Across Asia and Australia $HCM HUTCHMED Completes Enrollment for Phase II Trial of Fanregratinib in Liver Cancer Patients $RVLV Revolve Group And Muus Collective, Inc. Announced The Worldwide Launch Of BELLEMINT, The Cutting-edge Fashion Styling Game That Seamlessly Merges Interactive Play With Real-world Shopping $CFLT Confluent Announced Sccc By Stc—A Leading Cloud Services Provider In Saudi Arabia—Has Joined The Confluent OEM Program As A Managed Service Provider (MSP) To Make Data Streaming More Accessible In Saudi Arabia

$HCM: At $14.83 showing promise. Buy near $14.50 target $17.00 with pharmaceutical expansion.

$HCM: Hutchmed China Ltd ADR at $14.79 is steady. Buy near $14.50 and target $17.00 with pharmaceutical expansion.

$HCM We are buying from $13-11, Hold.

$HCM I'm still waiting for my entry at $12-11.9 I believe the bottom was at $7+.

$HCM https://www.globenewswire.com/news-release/2025/01/01/3003243/0/en/hutchmed-announces-us-608-million-divestment-of-non-core-joint-venture.html

$NMRA announced that the Phase 3 KOASTAL-1 study of navacaprant for major depressive disorder did not show a statistically significant improvement in the primary endpoint of change in MADRS score at Week 6 or the key secondary endpoint of SHAPS score. The KOASTAL-2, KOASTAL-3, and KOASTAL-LT studies are ongoing. See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/neumora-nmra-phase-3-fail-tc-biopharm-negotiations-update $TCNBP $CRIS $CMND $HCM $SIGA